EUVIMEDEUVIMED entdecken
Crossref

LINC00319 Promotes Cervical Cancer Progression Via Targeting miR-147a/IGF1R Pathway

Zhe Ma, Yufei Cai, Limei Zhang, Chenchen Tian, Lin Lyu

Cancer Biotherapy and Radiopharmaceuticals · 2020

DOI: 10.1089/cbr.2020.3722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2020. Verfasst von Zhe Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Affiliated Hospital of Beihua University, Jilin City, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, MicroRNAs, RNA, Long Noncoding, Receptor, IGF Type 1. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cervical cancer is identified as the fourth most common female malignancy worldwide. Recently, Linc00319 was reported to play an important role in the development and progression of cervical cancer. However, little is known about the molecular mechanism and clinical significance of Linc00319 in the carcinogenesis of cervical cancer. This study aims to reveal the biological function and molecular mechanisms of Linc00319 in cell proliferation, invasion, and migration of cervical cancer. MATERIALS AND METHODS: In the current study, gene expression levels of Linc00319, miR-147a, and IFG1R were detected by quantitative real-time PCR in clinical tissue samples and cervical cancer cell lines. Protein levels were also determined by western blot assay in cervical cancer cells. CCK-8, transwell, and wound healing assays were used to test the proliferation, invasion, and migration of cervical cancer cell lines in vitro. Target genes were predicted through bioinformatics methods and then verified by gene engineering technology. RESULTS: The authors' results showed that Linc00319 was upregulated in cervical cancer tissues and cell lines, while Linc00319silencing could inhibit cervical cancer cell proliferation, invasion, and migration. Further investigations showed that Linc00319 interacted with miR-147a and inhibited its expression, unregulated IGF1R to induce progression of cervical cancer. CONCLUSIONS: Their research indicated that Linc00319 might play an oncogenic role in cervical cancer and regulate the progression of cervical tumor growth by inhibiting the expression of miR-147a and activating IGF1R-related pathway. The findings suggest a novel molecular biomarker and therapeutic target for cervical tumor and may provide a novel therapeutic strategy for preventing the metastasis of cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsMicroRNAsRNA, Long NoncodingReceptor, IGF Type 1HumansFemaleCell ProliferationDisease ProgressionCell MovementGene Expression Regulation, NeoplasticCell Line, TumorSignal TransductionMiddle Aged

Stichwörter der Autor:innen

Linc00319cervical cancerinsulin-like growth factor 1 receptormiR-147a

Substanzen

MicroRNAsRNA, Long NoncodingIGF1R protein, humanReceptor, IGF Type 1

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Affiliated Hospital of Beihua University, Jilin City, China.
  • Department of Gynecology, The First Affiliated Hospital of Chengdu Medical College, Chengdu City, China.

Zitieren

APA

Ma, Z., Cai, Y., Zhang, L., Tian, C., & Lyu, L. (2020). LINC00319 Promotes Cervical Cancer Progression Via Targeting miR-147a/IGF1R Pathway. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2020.3722

Vancouver

Ma Z, Cai Y, Zhang L, Tian C, Lyu L. LINC00319 Promotes Cervical Cancer Progression Via Targeting miR-147a/IGF1R Pathway. Cancer Biotherapy and Radiopharmaceuticals. 2020. doi:10.1089/cbr.2020.3722

BibTeX
@article{Ma2020,
  author = {Ma, Zhe and Cai, Yufei and Zhang, Limei and Tian, Chenchen and Lyu, Lin},
  title = {LINC00319 Promotes Cervical Cancer Progression Via Targeting miR-147a/IGF1R Pathway},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2020},
  doi = {10.1089/cbr.2020.3722}
}
Kostenlos starten →